2018 New Idea Awards

The New Idea Award recognizes researchers who are investigating potentially transformative ideas to significantly improve clinical outcomes for patients with blood cancers. These research projects may eventually lead to significant improvements in the clinical outcomes of patients with hematological malignancies.

Donate Today


New Idea Awardees

Dr. Katherine Borden

University of Montréal          
​Montréal, Québec Blood cancer type acute myeloid leukemia (AML)   The study eIF4E drives production of extracellular vesicles in AML   Dysregulation of a cancer-causing protein, eIF4E, is linked to many cancers including cute myeloid leukemia (AML). We discovered that eIF4E overexpression dri...

Dr. Colin Crist

Jewish General Hospital/Lady Davis Institute for Medical Research         
​Montréal, Québec Co-Applicant: Dr. Trang Hoang
IRIC, University of Montréal Blood cancer type
Pediatric acute lymphoblastic leukemia (ALL)   The study Targeting eIF2(alpha) phosphorylation in T-cell acute lymphoblastic leukemia     ...

Dr. Kolja Eppert

McGill University Health Centre           
​Montréal, Québec Co-Applicant: Dr. Margret Shirinian​
American University of Beirut Blood cancer type
leukemia   The study Novel Histone Mutations in Leukemia   Leukemia often develops when the master genes that govern how all other genes are ‘read’ are broke...

Dr. Etienne Gagnon

University of Montréal          
​Montréal, Québec Blood cancer type
leukemia   The study Self-Assembling Multi-Subunit Chimeric Antigen Receptors to Target Leukemia Current therapies using chimeric antigen receptor (CAR) therapy show great success in treating patients with various types of leukemia. However, this approach has be...

Dr. Dixie Mager

British Columbia Cancer Agency         
Vancouver, BC Blood cancer type
leukemia   The study The onco-ribosome as a novel drug target in leukemias​ In our lab, we discovered a cancer-specific variation in T-cell leukemia in the ribosome, a cell component essential to synthesize proteins. Interestingly, this variation is located in a ribo...

Dr. Mark Minden

University Health Network   
Toronto, ON Blood cancer type
acute myeloid leukemia (AML)
The study High level expression of SOCS2 in high risk acute myeloid leukemia SOCS2 is a protein which suppresses cytokine signaling and is encoded on chromosome 12. It appears to inhibit Acute Myeloid Leukemia (AML) cell growth by targeting and binding to several key proteins within...